A Collaboration of Stand Up To Cancer, Ovarian Cancer Research Fund, Ovarian Cancer National Alliance and National Ovarian Cancer Coalition
Up to $6 million grant available; Letter of Intent deadline is Nov. 7, 2014PHILADELPHIA—- September 18, 2014 — The American Association for Cancer Research (AACR) is now accepting submissions of ideas for the Stand Up To Cancer (SU2C)-Ovarian Cancer Research Fund (OCRF)-Ovarian Cancer National Alliance (OCNA)-National Ovarian Cancer Coalition (NOCC) Translational Research Dream Team Grant that will offer up to $6 million in research funding.
The SU2C-OCRF-OCNA-NOCC Translational Research Dream Team grant provides three years of funding for research projects that must include therapeutic interventions for ovarian cancer and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional Dream Team of experts. Proposals for the grant must describe plans indicating how the group will use a transformative and synergistic approach, and how the work will be translated into the clinic. To maximize creativity, innovation, and collaboration, the projects should span multiple disciplines and use modern scientific tools to attack research questions in a coordinated effort.
A Joint Scientific Advisory Committee (JSAC) appointed by SU2C, OCRF, OCNA, and NOCC will conduct a unique, interactive, rapid, and rigorous evaluation of the applications via a multistep scientific review process. The JSAC is comprised of highly accomplished senior laboratory researchers and physician-scientists, as well as advocates.
The committee is chaired by Arnold J. Levine, PhD, professor at the Institute for Advanced Study in Princeton, New Jersey, and at the Cancer Institute of New Jersey in New Brunswick. William G. Nelson, MD, PhD, director of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, and Jeff Boyd, PhD, senior vice president at the Fox Chase Cancer Center in Philadelphia and chair of OCRF’s Scientific Advisory Committee, will serve as vice-chairs.
Letters of Intent for SU2C-OCRF-OCNA-NOCC Translational Research Dream Team Grant are due by noon ET, Nov. 7, 2014, via proposalCENTRAL at https://proposalcentral.altum.com/default.asp?GMID=39
For general information on eligibility criteria, the application process, and other details about this Dream Team grant, visit http://www.aacr.org/su2cfunding/dreamteam. Inquiries may be directed to the AACR Scientific Review and Grants Administration Department at 267-765-1049 or firstname.lastname@example.org.
The SU2C-OCRF-OCNA-NOCC Translational Research Dream Team Grant recipients are scheduled to be announced in spring 2015.
# # #Media Contacts:
About Stand Up To Cancer
Stand Up To Cancer (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a program of the Entertainment Industry Foundation (EIF), a 501(c)(3) charitable organization, was established in 2008 by film and media leaders who utilize the industry’s resources to engage the public in supporting a new, collaborative model of cancer research, and to increase awareness about cancer prevention as well as progress being made in the fight against the disease.
Current members of the SU2C Council of Founders and Advisors (CFA) include Katie Couric, Sherry Lansing, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, Ellen Ziffren, and Kathleen Lobb. The late co-founder Laura Ziskin executive produced both the Sept. 5, 2008, and Sept. 10, 2010, broadcasts. Lisa Paulsen and Pam Williams were executive producers, and the other CFA members were co-producers, of the 2014 telecast. SU2C was formally launched on May 27, 2008. Sung Poblete, Ph.D., R.N., has served as SU2C’s president and CEO since 2011.
In addition to “Visionary” donors Major League Baseball, Cancer Treatment Centers of America, MasterCard, and The Sidney Kimmel Foundation for Cancer Research, other major donors and collaborators that are currently engaged with SU2C include Genentech, Prostate Cancer Foundation, American Cancer Society, The Safeway Foundation, Bristol-Myers Squibb, KWF (The Dutch Cancer Society), St. Baldrick’s Foundation, Lustgarten Foundation, Cancer Research UK, Sean Parker Foundation, Fox Family Cancer Research Funding Trust, Fifth Third Bank, Melanoma Research Alliance, Cancer Research Institute, Room Key, Ovarian Cancer Research Fund, Ovarian Cancer National Alliance, National Ovarian Cancer Coalition, Laura Ziskin Family Trust, Farrah Fawcett Foundation, and Siemens.
For more information on Stand Up To Cancer, please visit http://www.standup2cancer.org.
About Ovarian Cancer Research Fund
Ovarian Cancer Research Fund (OCRF), founded in 1994, is the oldest and largest charity in the United States funding ovarian cancer research, and ranks third in overall ovarian cancer research funding only after the National Cancer Institute (NCI) and the Department of Defense (DOD). Its mission is to fund scientific research that leads to more effective identification, treatment, and ultimately a cure for ovarian cancer, as well as related educational and support initiatives. OCRF has invested nearly $60 million in ovarian cancer research through 217 grants to scientists at 65 leading medical centers in the United States. OCRF continues to take the lead in funding the best and most promising ovarian cancer research while supporting women and their loved ones affected by the disease in our quest to end it. For more information, please visit http://www.ocrf.org.
About Ovarian Cancer National Alliance
The Ovarian Cancer National Alliance (OCNA) has been a powerful voice for everyone touched by ovarian cancer since its founding in 1997. OCNA connects survivors, women at risk, caregivers and health providers with the information and resources they need. They ensure that ovarian cancer is a priority for lawmakers and agencies in Washington, DC, and throughout the country and help the community to raise their voices on behalf of every life that has been affected by this disease.
About National Ovarian Cancer Coalition
Since its inception in 1995, the National Ovarian Cancer Coalition (NOCC) has been committed to raising awareness, promoting education, and funding research in support of women, families, and communities touched by ovarian cancer. NOCC is well-established as an important national advocate for patients and families struggling with ovarian cancer. NOCC remains steadfast in its mission to save lives by fighting tirelessly to prevent and cure ovarian cancer, and to improve the quality of life for survivors. For more information, please visit http://www.ovarian.org.
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s oldest and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 35,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and cancer advocates in 97 countries. The AACR convenes more than 20 conferences and educational workshops every year, the largest of which is the AACR Annual Meeting with over 18,000 attendees. The AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers and funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of SU2C, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual grants. For more information about the AACR, please visit http://www.AACR.org .